Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 49.8%

Financial News Live ·  {{timeTz}}

Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 77,000 shares, an increase of 49.8% from the June 30th total of 51,400 shares. Based on an average trading volume of 470,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.5% of the shares of the company are short sold.

Insider Transactions at Indaptus Therapeutics

In other news, CEO Jeffrey A. Meckler bought 19,727 shares of the firm's stock in a transaction dated Monday, June 6th. The stock was bought at an average price of $2.63 per share, for a total transaction of $51,882.01. Following the transaction, the chief executive officer now owns 45,374 shares in the company, valued at $119,333.62. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.30% of the company's stock.

Get Indaptus Therapeutics alerts:

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp acquired a new position in Indaptus Therapeutics during the 1st quarter valued at approximately $41,000. State Street Corp acquired a new position in Indaptus Therapeutics during the 1st quarter valued at approximately $78,000. Vanguard Group Inc. boosted its position in Indaptus Therapeutics by 18.7% during the 1st quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock valued at $969,000 after purchasing an additional 38,216 shares during the period. Finally, Investment House LLC boosted its position in Indaptus Therapeutics by 272.8% during the 4th quarter. Investment House LLC now owns 95,629 shares of the company's stock valued at $545,000 after purchasing an additional 69,976 shares during the period. Institutional investors and hedge funds own 22.26% of the company's stock.

Indaptus Therapeutics Price Performance

Shares of INDP traded down $0.10 during mid-day trading on Monday, hitting $2.74. The stock had a trading volume of 200 shares, compared to its average volume of 274,422. The company's fifty day simple moving average is $2.65 and its two-hundred day simple moving average is $3.48. Indaptus Therapeutics has a fifty-two week low of $1.89 and a fifty-two week high of $28.83.

Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, analysts forecast that Indaptus Therapeutics will post -1.85 EPS for the current year.

About Indaptus Therapeutics

(Get Rating)

Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.

Further Reading

  • Get a free copy of the research report on Indaptus Therapeutics (INDP)
  • The Colgate-Palmolive Growth Outlook Brightens
  • Deep Value High Yield Newell Brands Is Ready To Bottom
  • These Stocks Outperformed Last Time There Was A Recession
  • Does Rivian's Stock Still Have A Future?
  • Inflation Resistant Weyerhaeuser Company Might Get Cheaper

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top